论文部分内容阅读
目的:探讨血清胃泌素释放肽前体(ProGRP)和神经特异性烯醇化酶(NSE)对小细胞肺癌(SCLE)的诊断意义。方法:应用化学发光免疫分析技术测定小细胞肺癌患者、非小细胞肺癌患者、良性肺病患者和有肺转移的其他原发性肿瘤患者的血清ProGRP与NSE水平。结果:血清ProGRP与NSE诊断SCLC的敏感度分别为75.0%和58.3%,特异性分别为88.9%和86.1%;血清ProGRP和NSE水平在治疗有效前后有统计学差异。结论:ProGRP对SCLC的诊断性敏感度高,特异性强,比NSE与治疗的效果的相关性好,能更早的预示复发。
Objective: To investigate the diagnostic value of serum gastrin-releasing peptide precursor (ProGRP) and neuron-specific enolase (NSE) in patients with small cell lung cancer (SCLE). Methods: Serum ProGRP and NSE levels were measured using chemiluminescence immunoassay in patients with small cell lung cancer, non-small cell lung cancer, patients with benign lung disease, and other primary tumors with lung metastases. Results: The sensitivity of serum ProGRP and NSE in diagnosis of SCLC was 75.0% and 58.3%, respectively, the specificity was 88.9% and 86.1% respectively. Serum ProGRP and NSE levels were significantly different between before and after treatment. CONCLUSIONS: ProGRP is highly sensitive and specific for SCLC, which has a good correlation with NSE and the effect of treatment. It can predict the recurrence earlier.